197 related articles for article (PubMed ID: 12207631)
1. Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis.
Takayanagui OM; Bonato PS; Dreossi SA; Lanchote VL
Br J Clin Pharmacol; 2002 Aug; 54(2):125-30. PubMed ID: 12207631
[TBL] [Abstract][Full Text] [Related]
2. Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis.
Lanchote VL; Takayanagui OM; Mateus FH
Chirality; 2004 Oct; 16(8):520-5. PubMed ID: 15290687
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis.
Marques MP; Takayanagui OM; Bonato PS; Santos SR; Lanchote VL
Chirality; 1999; 11(3):218-23. PubMed ID: 10079501
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis.
Lanchote VL; Garcia FS; Dreossi SA; Takayanagui OM
Ther Drug Monit; 2002 Jun; 24(3):338-45. PubMed ID: 12021623
[TBL] [Abstract][Full Text] [Related]
5. Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.
Marques MP; Takayanagui OM; Lanchote VL
Braz J Med Biol Res; 2002 Feb; 35(2):261-9. PubMed ID: 11847531
[TBL] [Abstract][Full Text] [Related]
6. Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis.
Arroyo G; Bustos JA; Lescano AG; Gonzales I; Saavedra H; Rodriguez S; Pretell EJ; Bonato PS; Lanchote VL; Takayanagui OM; Horton J; Gonzalez AE; Gilman RH; Garcia HH;
Clin Infect Dis; 2019 Nov; 69(11):1996-2002. PubMed ID: 30715265
[TBL] [Abstract][Full Text] [Related]
7. A simple LC-MS/MS method to determine plasma and cerebrospinal fluid levels of albendazole metabolites (albendazole sulfoxide and albendazole sulfone) in patients with neurocysticercosis.
González-Hernández I; Ruiz-Olmedo MI; Cárdenas G; Jung-Cook H
Biomed Chromatogr; 2012 Feb; 26(2):267-72. PubMed ID: 21721022
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous liquid chromatography-tandem mass spectrometric determination of albendazole sulfoxide and albendazole sulfone in plasma.
Bonato PS; Lanchote VL; Takayanagui OM
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):237-45. PubMed ID: 12450544
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic optimisation of the treatment of neurocysticercosis.
Sotelo J; Jung H
Clin Pharmacokinet; 1998 Jun; 34(6):503-15. PubMed ID: 9646011
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of albendazole in children with neurocysticercosis.
Jung H; Sánchez M; González-Astiazarán A; Martínez JM; Suástegui R; González-Esquivel DF
Am J Ther; 1997 Jan; 4(1):23-6. PubMed ID: 10423586
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its active metabolite albendazole sulfoxide.
Zeugin T; Zysset T; Cotting J
Ther Drug Monit; 1990 Mar; 12(2):187-90. PubMed ID: 2315975
[TBL] [Abstract][Full Text] [Related]
12. Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis.
Paias FO; Lanchote VL; Takayanagui OM; Bonato PS
Electrophoresis; 2001 Sep; 22(15):3263-9. PubMed ID: 11589289
[TBL] [Abstract][Full Text] [Related]
13. Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.
Gokbulut C; Cirak VY; Senlik B
Vet Res Commun; 2006 Oct; 30(7):791-805. PubMed ID: 17004041
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of albendazole in patients with neurocysticercosis.
Castro N; Márquez-Caraveo C; Brundage RC; González-Esquivel D; Suárez AM; Góngora F; Jara A; Urizar J; Lanao JM; Jung H
Int J Clin Pharmacol Ther; 2009 Nov; 47(11):679-85. PubMed ID: 19840532
[TBL] [Abstract][Full Text] [Related]
15. Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity.
Lima RM; Ferreira MA; de Jesus Ponte Carvalho TM; Dumêt Fernandes BJ; Takayanagui OM; Garcia HH; Coelho EB; Lanchote VL
Br J Clin Pharmacol; 2011 Apr; 71(4):528-35. PubMed ID: 21395645
[TBL] [Abstract][Full Text] [Related]
16. Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?
Fabbri J; Espinosa JP; Pensel PE; Medici SK; Gamboa GU; Benoit JP; Elissondo MC
Acta Trop; 2020 Jan; 201():105215. PubMed ID: 31600525
[TBL] [Abstract][Full Text] [Related]
17. Aspects of the pharmacokinetics of albendazole sulphoxide in sheep.
Goudah A
Vet Res Commun; 2003 Oct; 27(7):555-66. PubMed ID: 14609267
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.
Garcia HH; Lescano AG; Lanchote VL; Pretell EJ; Gonzales I; Bustos JA; Takayanagui OM; Bonato PS; Horton J; Saavedra H; Gonzalez AE; Gilman RH;
Br J Clin Pharmacol; 2011 Jul; 72(1):77-84. PubMed ID: 21332573
[TBL] [Abstract][Full Text] [Related]
19. Disposition kinetics of albendazole and metabolites in laying hens.
Bistoletti M; Alvarez L; Lanusse C; Moreno L
J Vet Pharmacol Ther; 2013 Apr; 36(2):161-8. PubMed ID: 22533477
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent systemic exposure of albendazole metabolites in lambs.
Alvarez L; Suárez G; Ceballos L; Moreno L; Lanusse C
J Vet Pharmacol Ther; 2012 Aug; 35(4):365-72. PubMed ID: 21819410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
